PSA levels in darolutamide recipients are associated with risk for progression of nonmetastatic castration-resistant prostate cancer (nmCRPC).
SUO 2023: Androgen Receptor Agonist versus Antagonist: Cardiac Morbidity
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
ESMO 2023: Tolerance and Long-Term Side-Effects
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
JNM Releases Consensus on Lu-177 PSMA-617 Therapy Use
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.